Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology

 Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology

Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology

Shots:

  • Boehringer Ingelheim acquires ICD Therapeutics in all stock transaction, to utilize ICD’s MacroDel biologics-delivery platform to develop oncology therapies for intracellular delivery of macromolecules (peptides and proteins)
  • The focus of the acquisition is to enhance Boehringer’s oncology portfolio with the development of therapies for intracellular targets for tumor cell types
  • ICD’s MacroDel technology is a novel biologics-delivery platform targeting transporter proteins in the cell membrane to deliver therapies intracellularly. Additionally, BI will collaborate with nanoPET Pharma (former share holder of ICD Therapeutics) to develop therapies with ICD’s platform

Click here to read full press release/ article | Ref: Boehringer Ingelheim | Image: Missouri Business Alert

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post